A phase III randomized trial of gantenerumab in prodromal Alzheimer’s diseasePaulo Fontoura, Susanne Ostrowitzki, Robert Lasser et al.|Alzheimer s Research & Therapy|2017Cited by 568
Amyloid‐Related Imaging Abnormalities in the <scp>DIAN‐TU</scp>‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph‐Mathurin, Richard J. Perrin, Jakub Wojtowicz et al.|Annals of Neurology|2022Cited by 42
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J. Bateman, Bruno Dubois, Yan Li et al.|The Lancet Neurology|2025Cited by 39